Biocon's Insulin manufacturing facility in Malaysia completes USFDA (PAI) inspection

24 Feb 2020 Evaluate

US Food and Drug Administration (USFDA) has conducted a pre-approval inspection (PAI) of Biocon’s subsidiary -- Biocon Sdn. Bhd's Insulins manufacturing facility based in Malaysia, for Insulin Glargine, between February 10 and February 21, 2020. At the conclusion of the inspection, the agency has issued a Form 483 with 3 observations.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

366.55 -9.45 (-2.51%)
20-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.00
Dr. Reddys Lab 1166.90
Cipla 1377.85
Zydus Lifesciences 872.95
Lupin 2166.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×